Theravance Biopharma, Inc. (TBPH) Form SCHEDULE 13D/A — Sep 25, 2026
Weiss Asset Management and affiliated entities filed Amendment No. 4 to their Schedule 13D on Theravance Biopharma, reporting a stake of zero shares (0.0%) as of September 23, 2026. The reduction to zero reflects that Theravance's ordinary shares were cancelled on September 23, 2026 upon completion of the merger with Zymeworks Inc. The filing notes the Reporting Persons effected no transactions in the shares during the prior 60 days.
Key figures
- Shares Outstanding
- 51918754
- Acquirer
- Zymeworks Inc.
- Merger completion date
- 2026-09-23
- Reporting persons ownership
- 0 shares, 0.0%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.